Pre-mixed, ready-to-use pharmaceutical compositions

Details Pre-mixed, ready-to-use pharmaceutical compositions Pre-mixed, ready-to-use pharmaceutical compositions

2007-04-18

2009-11-03

Woodward, M P (Department: 1615)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C424S400000

Reexamination Certificate

active

07612102

ABSTRACT:
Provided herein are ready-to-use premixed pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions.

REFERENCES:
patent: 3985758 (1976-10-01), Murakami
patent: 4711902 (1987-12-01), Serno
patent: 4880823 (1989-11-01), Ogawa et al.
patent: 4940556 (1990-07-01), MacFarlane
patent: 5079237 (1992-01-01), Husu et al.
patent: 5164405 (1992-11-01), McFarlane et al.
patent: 5198226 (1993-03-01), MacFarlane
patent: RE34618 (1994-05-01), Ogawa
patent: 5376645 (1994-12-01), Stella
patent: 5519012 (1996-05-01), Fercej-Temeljotov
patent: 5904929 (1999-05-01), Uekama
patent: 6595926 (2003-07-01), Laragh
patent: 2007/0112041 (2007-05-01), Bhowmick
patent: 2007/0244166 (2007-10-01), Gupta
patent: 0149475 (1985-07-01), None
patent: 0162705 (1985-11-01), None
patent: 2228412 (1990-08-01), None
patent: WO 01/07086 (2001-02-01), None
Kaise, Barb, Patrick D. Eagan, and Hollie Shaner, Solutions to Health Care Waste: Life-Cycle Thinking and “Green” Purchasing, Environmental Health Perspectives, vol. 109, No. 3, Mar. 2001, pp. 1-4.
Pomponio, R., J. Fiori, V. Cavrini, P. Mura, M. Cirri and F. Maestrelli, Photostability studies on nicardipine-cyclodextrin complexes by capillary electrophoresis, Journal of Pharmaceutical and Biomedical Analysis 35 (2004) 267-275.
Yang et al., “Nicardipine versus nitroprusside infusion as antihypertensive therapy in hypertensive emergencies,” J. Int Med Research, vol. 32(2):118-123 (Mar.-Apr. 2004).
Atlee et al., “The use of esmolol, nicardipine, or their combination to blunt hemodynamic changes after laryngoscopy and tracheal intubation,” Anesth Analg, vol. 90:280-285 (Feb. 2000).
Aya et al., “Intravenous nicardipine for severe hypertension in pre-eclampsia—effects on mother and foetus,” Intensive Care Med., vol. 25(11):1277-1281 (Nov. 1999).
Cheung et al., “Nicardipine intravenous bolus dosing for acutely decreasing arterial blood pressure during general anesthesia for cardiac operations: pharmacokinetics, pharmacodynamics, and associated effects on left ventricular function,” Anesth Analg, vol. 89:1116-1133 (Nov. 1999).
Colson et al., “Haemodynamic heterogeneity and treatment with the calcium channel blocker nicardipine during phaeochromocytoma surgery,” Act Anaesthesiol Scand,, vol, 42(9):1114-1119 (Oct. 1998).
Elatrous et al., “Short-term treatment of severe hypertension of pregnancy: prospective comparison of nicardipine and labetalol,” Intensive Care Med., vol. 28(9):1281-1286 (Jul. 26, 2002).
Fernandes et al., “Physiochemical characterization and in vitro dissolution behavior of nicardipine-cyclodextrins inclusion compounds,” Eur. J. of Pharma. Sci. 15: pp. 79-88, 2002.
Flynn et al., “Intravenous nicardipine for treatment of severe hypertension in children,” J Pediatr., vol. 139(1):38-43 (Jul. 2001).
Kwak et al., “Comparison of the effects of nicardipine and sodium nitroprusside for control of increased blood pressure after coronary bypass graft surgery,”J Int Med Res, vol. 32:342-350 (Jul.-Aug. 2004).
Vincent et al., “Intravenous nicardipine in the treatment of postoperative arterial hypertension,”J Cardiothorac Vasc Anesth, vol. 11(2):160-164 (Apr. 1997).
Non Final Office Action for U.S. Appl. No. 11/737,067, dated Oct. 29, 2008.
PDL Biopharma, Inc.; “Cardene IV (nicardipine hydrochloride),” Product Insert, Jan. 2006, USA.
Sweetana and Akers, “Solubility principles and practices for parenteral drug dosage form development,” PDA J Pharmaceutical Science & Technology, 50(5):330-342 (1996).
Zhang et al., “The use of nicardipine for electroconvulsive therapy: a dose-ranging study,” Anesth Analg, vol. 100:378-381 (Feb. 2005).
Endoh et al., “Effects of nicardipine-, nitroglycerin-, and prostaglandin E1-induced hypotension on human cerebrovascular carbon dioxide reactivity during propofol-fentanyl anesthesia,” J Clin Anesth, vol. 11(7):545-549 (Nov. 1999).
Bernard et al., “Long-term hypotensive technique with nicardipine and nitroprusside during isoflurane anesthesia for spinal surgery,” Anesth Analg., vol. 75(2):179-185 (Aug. 1992).
Chen et al., “The comparative potentcy of intravenous nicardipine and verapamil on the cardiovascular response to tracheal intubation,” Acta Anaesthesiol Sin., vol. 34(4):197-202 (Dec. 1996).
Song et al., “Optimal dose of nicardipine for maintenance of hemodynamic stability after tracheal intubation and skin incision,” Anesth Analg, vol. 85:1247-1251 (Dec. 1997).
Cheung et al., “Acute pharmacokinetic and hemodynamic effects of intravenous bolus dosing of nicardipine,” Am Heart J., vol. 119(2 Pt 2):438-442 (Feb. 1990).
Yalkowsky et al., “Formulation-related problems associated with intravenous drug delivery,” J Pharm Sciences, vol. 87(7):787-796 (Jul. 1998).
Maurin et al., “Solubilization of nicardipine hydrochloride via complexation and salt formation,” J Pharm Sciences, vol. 83(10):1418-1420 (Oct. 1994).

Affiliated with

Also associated with

Rating

Pre-mixed, ready-to-use pharmaceutical compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pre-mixed, ready-to-use pharmaceutical compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pre-mixed, ready-to-use pharmaceutical compositions will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4126904